

02 July 2012: Net Tangible Asset (NTA) Backing – June 2012

30 June 2012			Cost Price			Board Valuation ¹		
	Company	ASX Code		Cost Price	Cents per BTC share	Cu	rrent Value*	Cents per BTC share
UNL	ISTED SECURITIES							
1	Biocomm		\$	1,235,701	1.66c	\$	1,235,701	1.66c
2	Generic Health		\$	2,200,000	2.95c	\$	2,200,000	2.95c
3	Sensear		\$	3,116,761	4.18c	\$	3,338,984	4.48c
	General Provision				0.00c	-\$	2,723,668	-3.65c
TOTAL UNLISTED SECURITIES			\$	6,552,463	8.79c	\$	4,051,017	5.43c
	Cash		\$	876,888	1.18c	\$	876,888	1.18c
Tax Provision			\$	-	0.00c	\$	-	0.00c
TOTAL			\$	7,429,351	9.97c	\$	4,927,905	6.61c

¹ Board Valuation as defined by BioTech Capital's Investment policy including provision for tax

BioTech Capital issued capital:

Ordinary Shares

74,554,108

Commentary - activities during the last month

The entire holding in ASX-listed Neurodiscovery Ltd was disposed of at a price of 2.5 cents per share.

Valuations

The "Board Valuation" column is based upon the investment policy of the Board and is broadly in line with industry standard practices.

About BioTech Capital Ltd

BioTech Capital Ltd ("BTC") is a listed investment fund currently conducting an orderly wind-down of its holdings pursuant to a change in investment activity approved by shareholders in 2010. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.biotechcapital.com.au

Contact Information

Harry Karelis, Director, Biotech Capital Ltd, Ph: +61 413 056 328, E-mail: hkarelis@titancapitalpartners.com.au

1 Edmondson Crescent Karrinyup WA 6018 Australia **T**+61 413 056 328 **F**+61 8 9327 1778